Karyopharm Therapeutics Investor Presentation — January 2019

Document content

JP Morgan Healthcare Conference

Targeting Disease at the Nuclear Pore2Forward -looking Statements and Other Important Information

This presentation contains forward -looking statements within themeaning ofthe“safe harbor” provisions ofThe Private Securities Litigation Reform Actof1995 .Such

forward -looking statements include those regarding thetherapeutic potential ofand potential clinical development plans and commercialization forKaryopharm’s drug

candidates, including thetiming ofinitiation ofcertain trials, ofthereporting ofdata from such trials, ofthesubmissions toregulatory authorities andofpotential commercial

launches, thepotential availability ofaccelerated approval pathways, thepotential sizeofthemarkets formultiple myeloma drugs andmultiple myeloma drugs fortreatment of

patients with relapsed multiple myeloma andKaryopharm’s strategic andfinancial plans andexpectations aswellasfinancial projections forKaryopharm .Such statements

aresubject tonumerous important factors, risks anduncertainties thatmay cause actual events orresults todiffer materially from Karyopharm’s current expectations .For

example, there canbenoguarantee thatregulators willagree thatselinexor qualifies foraccelerated approval intheU.S.orconditional approval intheE.U.asaresult ofthe

data from theSTORM study inpatients with penta -refractory myeloma orSADAL study inpatients with relapsed/refractory DLBCL orthat any ofKaryopharm’s drug

candidates, including selinexor (KPT -330) andeltanexor (KPT -8602 ),Karyopharm’s second generation SINE compound, orKPT-9274, Karyopharm’s first-in-class oraldual

inhibitor ofPAK4 andNAMPT, oranyother drug candidate Karyopharm isdeveloping, willsuccessfully complete necessary preclinical andclinical development phases orthat